Syringe services programs (SSPs), sometimes known as “needle exchange,” are a long- standing, evidence-based practice that is a core component of harm reduction services. Syringe access in the United States began in 1988 in an effort to stop the spread of HIV among people who injected drugs. In October 2021, the U.S. Department of Health […]
Fact Sheet: Health Centers and Syringe Services Programs Read More >>
Comments on the Expansion of Induction of Buprenorphine via Telemedicine Encounter (Docket No. DEA-948) Download Document (PDF)
Overdose deaths in the United States have reached epidemic levels, with over 100,000 deaths reported between April 2020 and April 2021. Approximately 75% of those deaths were caused by opioids (driven by the synthetic opioid fentanyl), which makes preventing opioid-related overdoses and expanding access to opioid-use disorder (OUD) treatment specifically important. People experiencing homelessness are
Webinar Slides(PDF) NHCHC MAT Policy Brief(PDF) Project HOPE Medication First Model(PDF) Project HOPE Addiction Laguage Guide(PDF) Buprenorphine Research on New Approaches article(PDF) While Health Care for the Homeless programs serve only 4% of all health center patients nationally, they are responsible for serving nearly 40% of all patients receiving medication-assisted treatment (MAT). Patient need
Medication-Assisted Treatment in the HCH Community: Strategies for Expanding Services Read More >>
Health Care for the Homeless (HCH) programs, a subset of community health centers that receive special populations funding to address the specific needs of vulnerable and medically complex patients, play a significant role in addressing the opioid epidemic by providing medication-assisted treatment (MAT). MAT, which combines one of three medications (methadone, buprenorphine, or naltrexone) with
